Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran autogene + Pembrolizumab in First-Line Advanced Melanoma (INTerpath-012)
NCT06961006Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Jul 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 12
01
Overview
A Phase 2 trial of intismeran autogene in melanoma, sponsored by Merck & Co.. Started May 2025; status: recruiting.
02
Drugs
intismeran autogene
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06961006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961006.